103 related articles for article (PubMed ID: 15652242)
1. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
Richter T; Schwab M; Eichelbaum M; Zanger UM
Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
3. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms.
Harleton E; Webster M; Bumpus NN; Kent UM; Rae JM; Hollenberg PF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1011-9. PubMed ID: 15121764
[TBL] [Abstract][Full Text] [Related]
5. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.
Rae JM; Soukhova NV; Flockhart DA; Desta Z
Drug Metab Dispos; 2002 May; 30(5):525-30. PubMed ID: 11950782
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
7. A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.
Walsky RL; Obach RS
Drug Metab Dispos; 2007 Nov; 35(11):2053-9. PubMed ID: 17682072
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
Sridar C; Kenaan C; Hollenberg PF
Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Nirogi R; Palacharla RC; Mohammed AR; Manoharan A; Ponnamaneni RK; Bhyrapuneni G
Chem Biol Interact; 2015 Mar; 230():9-20. PubMed ID: 25656918
[TBL] [Abstract][Full Text] [Related]
12. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
Nishiya Y; Hagihara K; Ito T; Tajima M; Miura S; Kurihara A; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
[TBL] [Abstract][Full Text] [Related]
14. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
15. Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6.
Lin HL; Zhang H; Hollenberg PF
J Pharmacol Exp Ther; 2009 Apr; 329(1):26-37. PubMed ID: 19168709
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Coles R; Kharasch ED
Pharm Res; 2008 Jun; 25(6):1405-11. PubMed ID: 18219560
[TBL] [Abstract][Full Text] [Related]
17. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China.
Kim H; Kim KB; Ku HY; Park SJ; Choi H; Moon JK; Park BS; Kim JH; Yea SS; Lee CH; Lee HS; Shin JG; Liu KH
Drug Metab Dispos; 2008 Jun; 36(6):1010-5. PubMed ID: 18332082
[TBL] [Abstract][Full Text] [Related]
19. Measurement of in vitro cytochrome P450 2B6 activity.
Walsky RL; Obach RS
Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
[TBL] [Abstract][Full Text] [Related]
20. The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity.
Seo KA; Kim H; Ku HY; Ahn HJ; Park SJ; Bae SK; Shin JG; Liu KH
Chem Biol Interact; 2008 Aug; 174(3):141-6. PubMed ID: 18611395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
